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Immunological Predictors of Nonresponse to Directly 
Acting Antiviral Therapy in Patients With Chronic 
Hepatitis C and Decompensated Cirrhosis
Kate Childs,1 Elliot Merritt,1 Aisling Considine,2 Alberto Sanchez-Fueyo,1 Kosh Agarwal,2 Marc Martinez-Llordella,1 and Ivana Carey2
1Liver Sciences, King’s College London, United Kingdom; and 2Institute of Liver Studies, King’s College Hospital, London, United Kingdom
Background. Sustained virological response rates (SVRs) to directly acting antiviral (DAA) therapy for hepatitis C virus (HCV) 
are lower in decompensated cirrhosis. Markers of innate immunity predict nonresponse to interferon-based HCV treatment; how-
ever, whether they are associated with the response to DAAs in patients with decompensation is not known.
Methods. Information on demographics, adherence, viral kinetics, and resistance were gathered prospectively from a cohort 
with decompensated cirrhosis treated with 12 weeks of DAAs. C-X-C motif chemokine-10 (CXCL-10) level and T-cell and natural 
killer (NK) cell phenotype were analyzed pretreatment and at 4 and 12 weeks of treatment.
Results. Of 32 patients, 24 of 32 (75%) achieved SVR (responders). Eight of 32 (25%) experienced relapse after the end of 
treatment (nonresponders). There were no differences in demographics or adherence between groups. Nonresponders had higher 
CXCL-10; 320 pg/mL (179 461) vs 109 pg/mL (88 170) in responders (P < .001) and differential CXCL-10 dynamics. Nonresponders 
had lower NK cell frequency, higher expression of activation receptor NKp30, and lower frequency of the NK subset CD56−CD16+.
Conclusions. Nonresponders to DAAs displayed a different NK phenotype and CXCL-10 profile to responders. Nonresponders 
did not have poorer adherence or baseline virological resistance, and this shows that immunological parameters are associated with 
treatment response to interferon-free treatment for HCV in individuals with decompensated cirrhosis.
Keywords. cirrhosis; directly acting antiviral; HCV; hepatitis C.
 
With the advent of directly acting antiviral (DAA) therapy for 
hepatitis C virus (HCV), there has been a great increase in the 
number of patients who can expect to achieve sustained viro-
logical response (SVR). In contrast to the historical treatment 
of pegylated interferon (IFN) and ribavirin, DAAs deliver SVR 
rates in the order of 90%–95% and higher [1, 2]. Suppression 
of HCV viral load is almost universal, but a small percentage 
of patients experience relapse posttreatment. Patients with 
decompensated cirrhosis have lower SVR rates than those 
with compensated cirrhosis, with 10%–15% experiencing 
virological relapse [3–5]. The reasons for this are not clearly 
defined but may include altered hepatic exposure to DAAs 
secondary to portosystemic shunting or the existence of viral 
reservoirs within the fibrotic matrix [6]. Tolerability of ribavirin- 
containing regimens is also poorer in decompensated disease. 
Little is known about predictors of failure to achieve SVR with 
DAAs. Although numerous clinical parameters predicted poor 
response to pegylated IFN treatment (eg, age, ethnicity, human 
immunodeficiency virus [HIV] coinfection, insulin resistance, 
and interleukin [IL]-28b genotype), none of them have been 
shown to be associated with virological relapse after DAA-
based therapy [1, 7–9].
One of the hallmarks of HCV persistence is the failure of 
both innate and adaptive antiviral immune responses to clear 
HCV. This results in continual immune activity in the presence 
of ongoing viremia. Hepatitis C virus ribonucleic acid (RNA) 
is detected in host cells by Toll-like receptor 3 (TLR-3) or cyto-
solic RIG-1 helicase-mediated pathways, leading to transcrip-
tional activation of type 1 IFN. Type 1 IFN binds to the cell 
surface receptor and activates the Jak-STAT pathway, which 
induces transcription of IFN-stimulated genes (ISGs), which 
have antiviral activity [10]. During chronic HCV infection, viral 
replication is sustained despite persistently high ISG expres-
sion. Increased type 1 IFNs also activate natural killer (NK) 
cells, which, in the context of HCV, display a polarized pheno-
type with increased cytotoxicity, proapoptotic TRAIL produc-
tion, and decreased cytokine production [11]. CD4 and CD8 
T-cell responses are elicited during acute HCV infection but are 
unable to contain the virus in most individuals; during chronic 
infection T-cell responses are only detectable at low levels [12]. 
Persistent antigenic stimulation results in T-cell exhaustion 
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with a sequential loss of antiviral function. The innate immune 
response contributes to the inadequacy of the adaptive response, 
because abrogation of IFN signaling in animal models reduces 
T-cell exhaustion [13]. One hypothesis is that this interaction 
protects the host from T cell-mediated damage in situations in 
which virus cannot be removed.
Features of the specific immune response seen in chronic 
HCV have been associated with a poor response to pegylated 
IFN [14–16]. Whether they are also associated with the response 
to DAAs has not yet been ascertained.
The UK Early Access Program was established specifically to 
treat patients with decompensated cirrhosis with IFN-free DAAs. 
Compared with other patient populations, this is a group that is 
more likely to experience treatment failure. Hence, it provides a 
unique opportunity (1) to clarify whether HCV-induced immune 
dysfunction influences virological response to DAAs and (2) to 
identify useful clinical or immunological predictors. In the current 
study, we prospectively followed a cohort of 32 decompensated 
cirrhotic patients. We gathered data on patient demographics, 
clinical parameters, viral factors, and adherence data. Sequential 
blood cell immunophenotyping and serum cytokine profiling 
were performed to explore the immunological consequences of 
HCV treatment and to identify predictors of response to therapy.
METHODS
Patient Cohort
We recruited all patient with chronic HCV infection and Child-
Pugh B or C cirrhosis who initiated treatment with DAAs at 
King’s College Hospital as part of the NHS England Early 
Access Program between August and November 2014. All 
patients were considered eligible to participate in the current 
study, provided they had not previously received a liver trans-
plant or were HCV-HIV coinfected. Patients received 12 weeks 
of sofosbuvir with either daclatasvir or ledipasvir. All patients 
received weight-based ribavirin. Patients who underwent liver 
transplantation or died during treatment or experienced major 
infectious complications were excluded from the final analysis. 
All patients provided written informed consent. Adherence 
data was gathered by questionnaire, patient self-report, and pill 
count at each clinic visit.
Treatment outcome was achieving SVR, which was defined as 
“response”, and failure to achieve an SVR, which includes viro-
logical relapse or breakthrough, was defined as “nonresponse”. 
In addition to the cirrhotic cohort, we later recruited a smaller 
cohort of noncirrhotic patients as a comparison group. These 
were patients who attended between March and June 2015 and 
were matched to the decompensated cirrhotic cohort by age, 
genotype, and gender (Supplementary Table).
Samples
Ethylenediaminetetraacetic acid plasma samples were taken 
pretreatment (TW0), at treatment week 4 (TW4), and at the 
end of treatment (TW12) and frozen at −80°C within 2 hours 
of the blood draw. Sodium heparin samples were taken at the 
same time point to isolate peripheral blood mononuclear cells 
(PBMCs) by density gradient centrifugation. The PBMCs were 
cryopreserved in freezing media at −140°C.
Hepatitis C Virus Viral Load Measurements
Hepatitis C virus RNA was assayed using the Roche 
COBAS AmpliPrep/COBAS TaqMan HCV Test, version 2.0. 
Nonresponders underwent retrospective next-generation 
sequencing for HCV resistance-associated mutations at base-
line and posttreatment with a threshold detection of 10% for 
NS3, NS5a, and NS5b regions.
Plasma Cytokine Levels
Measurement of the following cytokines was carried out using 
the Randox Biochip cytokine array (Randox Laboratories Ltd, 
Crumlin, London, UK): IL-1 α, IL-1β, IL-2, IL-4, IL-6, IL-8, 
IL- 10, IL-12, tumor necrosis factor-α, transforming growth fac-
tor (TGF)-β, and IL-17α. C-X-C motif chemokine-10 (CXCL-10), 
IFN-γ, and λ1, λ2, and λ3 were measured using IP-10 Quantikine 
ELISA, Human IFN-gamma Quantikine ELISA, and Human 
IL-29/IL-28B (IFN-lambda 1/3) DuoSet ELISA (R&D Systems 
Europe, Abingdon, UK).
Blood Immunophenotyping
We carried out immunophenotyping of total PBMC to quantify 
CD4 and CD8 effector T-cell subsets, T-regulatory (T-reg) cell fre-
quencies, and NK cell frequency and activation receptor profile. 
Flow cytometry was performed on a BD FACS Canto, and data were 
analyzed with FlowJo software (TriStar Inc., Ashland, OR) using 3 
panels of liquid monoclonal antibodies. All the experiments were 
performed on frozen PBMCs. To assess T cells, thawed PBMCs 
were labeled with allophycocyanin (APC) viability dye (Thermo 
Fisher Scientific, UK), APC Cy7 anti-CD4 (OKT4; BioLegend, 
London, UK), PerCP anti-CD8 (SK1; BioLegend), PE anti-CCR7 
(G043H7; BioLegend), PeCy7 anti-CD45RA (HI100; BioLegend), 
and fluorescein isothiocyanate (FITC) anti-PD-1 (clone E12.2H7; 
BioLegend). T-cell subsets were characterized as follows: naive T 
cells CD45RA+CCR7+, central memory T cells CD45RA−CCR7+, 
effector memory T cells CD45RA−CCR7−, and terminally differ-
entiated TEMRA effector cells CD45RA+CCR7−. T-regulatory 
cells were defined as CD4+CD25highFoxP3+ using FITC viability 
dye (Thermo Fisher Scientific, Northumberland, UK), APC Cy7 
anti-CD4 (OKT4; BioLegend, London, UK), and APC anti-CD25 
(2A3; BD Bioscience, Oxford, UK). In addition, intracellular Foxp3 
was performed after cell permeabilization (eBioscience, Scotland, 
UK) using PE anti-FOXP3 (259D; BioLegend). Natural killer T 
cells (NKT) and NK cells were defined as CD56+, CD3 positive 
and negative, respectively, and were stained with FITC viability 
dye (Thermo Fisher Scientific), PeCY7 CD3(eBioscience), APC 
Cy7 anti-CD56 (HCD56; BioLegend), PerCPCy5.5 anti-CD16 
(3G8; BioLegend), PE anti-NKp30 (Miltenyi Biotec, Bisley, UK), 
and APC anti-NKG2D (1D11; BioLegend).
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Statistical Analysis
Continuous variables are expressed as medians (interquartile 
range). Continuous variables were compared using Mann-
Witney U test, and discreet variables were compared using 
Fisher’s exact test. Univariate logistic analysis was carried out 
with treatment outcome as the dependent variable; variables 
that were significant in univariate were included in multivariate 
logistic analysis. P values of <.05 were deemed statistically sig-
nificant. All statistical analysis was carried out using SPSS (IBM 
SPSS Statistics V22.0).
RESULTS
Demographic Factors, Hepatitis C Virus (HCV) Virological Kinetics, HCV 
Resistance, and Adherence Do Not Differ Between Responders and 
Nonresponders to Directly Acting Antiviral Therapy
Of 47 patients treated under the Early Access Program within 
this time period, 7 had exclusion criteria and 8 developed a 
complication, ie, they received transplants or died before the 
end of treatment; therefore, 32 patients were included in the 
analysis. Twenty-four of 32 (75%) patients achieved SVR12 
and were defined as responders. Eight of 32 (25%) patients 
relapsed posttreatment and were defined as nonresponders. 
No patient experienced virological breakthrough on treat-
ment. All patients were cirrhotic with Child-Pugh score of 
B7 or greater. The majority of patients were men; ethnicity, 
age, gender, and model for endstage liver disease (MELD) 
score did not differ between responders and nonrespond-
ers, although there was a trend towards a higher prevalence 
of genotype 3 (G3) in the nonresponders. The majority of 
patients were treated with sofosbuvir/ledipasvir including 
4 of 6 patients with G3 in the responder group and 5 of 5 
patients with G3 in the nonresponder group. Demographics 
of the participants are shown in Table 1. All patients achieved 
undetectable HCV RNA by week 10, and 72% of patients 
achieved undetectable HCV by treatment week 8. There were 
no differences in baseline or on treatment HCV RNA levels 
between the responders and nonresponders at any timepoint. 
Adherence as measured by number of late or missed doses 
did not differ significantly between responders and nonre-
sponders (Table 2). After next-generation sequencing of the 
HCV virus in nonresponders at baseline and posttreatment, 
no patient had baseline resistance; however, 2 of the nonre-
sponders developed mutations in the NS5 region (1 devel-
oped Y93H, 1 developed Q30R).
Before Initiating Directly Acting Antiviral Therapy, Nonresponders Exhibit 
Higher CXCL10 Serum Level and Increased Frequency of Circulating 
NKp30-Positive Natural Killer Cells
Nonresponders had higher median pretreatment CXCL-10 lev-
els; 320 pg/mL (179 461) compared with 109 pg/mL (88 170) 
in responders (P < .001). To evaluate whether decompensated 
cirrhotic patients with HCV infection exhibit different CXCL-
10 serum levels than those observed in noncirrhotic patients, 
we recruited an additional cohort of 23 noncirrhotic patients. 
The median CXCL-10 level in this group was 258 pg/mL (range, 
163–368), which was significantly higher than the decompen-
sated responder group (P < .001) but not significantly different 
from the nonresponder group (P = .23).
The baseline NK cell phenotype differed between responders 
and nonresponders. Responders demonstrated a significantly 
higher NK cell frequency: 7.01% (4.3, 7.9) vs 4.3% (2.9, 5.3) in 
nonresponders (P = .018). Responders also had significantly 
higher frequencies of the NK subset CD56−CD16+ (P = .004). 
Total NKG2D expression did not differ between the groups, but 
total NKp30 expression on NK cells was significantly higher at 
Table 1. Baseline Demographic and Liver Disease Characteristics of Responders and Nonresponders to DAA Therapy
Characteristic Responders n = 24 Nonresponders n = 8 P Value for Comparison
Age 57 (46, 61) 58 (52, 63) ns
Male gender 13 (54%) 6 (75%) ns
Treatment regimen SOF/LDV 21 (87%) 8 (100%) ns
SOF/DCV 3 (13%) 0
Genotype 1 14 (58%) 2 (25%) ns
2 2 (8.5 %)  0
3 6 (25%) 5 (63%)
4 2 (8.5 %) 1 (12%)
Genotype 3 vs non-3 6 (25%) 5 (63%) .08
HCC 3 (12.5%) 3 (37.5%) .14
MELD score 12.5 (10.7, 14.2) 11 (9.7, 14.4) .3
Childs-Pugh Score B/C 20 CP B
4 CP C
8 CP B .5
Previous IFN-based HCV treatment Treatment naive 12 3 ns
Toxicity stop 4 2
Responder relapser 6 2
Nonresponder 2 1
Abbreviations: CP, Childs-Pugh; DCV, daclatasvir; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IFN, interferon; LDV, ledipasvir; MELD, model for end-stage liver disease; ns, not 
significant; SOF, sofosbuvir.
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baseline in nonresponders: 68.4% (range, 45.6–88.7) vs 38.9% 
(range, 15.8–67.5), P = .03 (Figure 3). Responders had signif-
icantly higher CD4 TEMRA at baseline compared with non-
responders: 7.7% (range, 3.8–11.4) vs 3.3% (range, 1.9–4.9), 
P = .03. Otherwise, no differences between the phenotype of 
CD4 and CD8 cells were found (Figure 4).
Of the cytokines assayed at baseline, only TGF-β was signif-
icant in univariate analysis, with higher levels associated with 
nonresponse (P  =  .04). In univariate analysis, with treatment 
outcome as the dependent variable, baseline CXCL-10, TGF-β, 
and total NKp30 and NK cell frequency were significant at the 
0.05 level. In the final logistic regression model of baseline vari-
ables, only CXCL-10 remained significant with a P value of .02, 
the model predicted 95% of responders to DAA therapy.
The Dynamics of CXCL-10 Serum Levels During Directly Acting Antiviral 
Treatment Differ Between Responders and Nonresponders
CXCL-10 was significantly higher in nonresponders than in 
responders both at baseline and at the end of treatment: 215 pg/mL 
(115 378) compared with 93 pg/mL (44 166) (P = .041) in 
responders. However, all of the nonresponders experienced a 
fall in CXCL-10 from baseline to TW4, and responders showed 
an increase in CXCL-10 from baseline to TW4 (P = .002 for 
difference in CXCL-10 fold change). Among responders, those 
who achieved undetectable HCV RNA by week 6 of treatment 
had a significantly greater fold increase in CXCL-10 at TW4 
compared with those who only suppressed HCV RNA at TW6 
or later (P = .04) (Figure 1). Nonresponse to DAA therapy is 
associated with lower NK cell frequency, elevated NK NKp30 
expression, and an increase in CD56−CD16+ NK cells during 
treatment.
Natural killer cell frequency was higher at baseline and TW4 
in responders; however, total NKp30 expression on NK cells 
was higher at baseline, on treatment, and at the end of treatment 
in nonresponders. No changes over the course of treatment in 
either responders or nonresponders were noted (Figure 3).
Baseline frequencies of the NK cell subset CD56−CD16+ 
were significantly higher in responders 5.1% (range, 2.5–8.5) 
than nonresponders 2.1% (range, 1.2–3.1) (P = .004). The 
frequency of the CD56−CD16+ population decreased over 
the course of treatment in responders but increased in non-
responders so that by the end of treatment, numbers were 
similar: 4.0% (2.5, 8.5) in responders and 3.8% (2.2, 5.1) 
in nonresponders (Figure 4). The fold change from pre-
treatment to end of treatment was significantly different 
between responders and nonresponders (P value for fold 
change = .001).
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Figure 1. C-X-C motif chemokine-10 ([CXCL-10] pg/mL) change over time by groups: rapid decline in hepatitis C virus (HCV) ribonucleic acid (RNA) (undetectable by week 
6 and achieved sustained virological response rate [SVR]), slower HCV RNA decline (undetectable after week 6 and achieved SVR), nonresponder (did not achieve SVR). The 
* signifies P < .05, the black line shows comparison between groups at a time point, and the gray box shows difference in fold change between groups over time.
Table 2. Virological Characteristics of Responders and Nonresponders to DAA Therapy
Characteristic Responders n = 24 Nonresponders n = 8 P Value
Baseline HCV RNA IU/mL 8.8 E5 (2.6 E7, 1.1 E6) 8.8 E5 (2.9E5, 2.1 E6) .6
TW4 HCV RNA IU/mL 15 (0, 15) 15 (3.7, 19.8) .3
TW12 HCV RNA IU/mL Not detected all patients Not detected all patients N/A
Number undetectable at TW4 10 (42%) 2 (25%) .3
Log drop HCV RNA TW0–TW4 4.8 (4.2, 5.4) 4.8 (4.2, 5.6) .8
Week achieved HCV RNA negative 6 (3.2, 6.7) 6 (4.5, 8) .2
Number of doses late/missed in 
12 weeks
1 (1, 2) 2 (1.5, 3.5) .1
Baseline resistance associated 
substitution (RAS)
N/A Wild-type virus in 8 of 8 patients N/A
Posttreatment RAS N/A 1 patient developed Y93H substitution in NS5a, 1 patient developed Q30R 
substitution in NS5a
N/A
Abbreviations: HCV, hepatitis C virus; N/A, nonapplicable; RAS, resistance-associated substitutions; RNA, ribonucleic acid; TW0, pretreatment; TW4, treatment week 4; TW12, end of 
treatment.
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The TGF-β was significantly higher at TW4 in nonrespond-
ers: 3.2  µg/L (range, 2.5–9.1) compared with 1.8  µg/L (range, 
1.5–2.6) in responders (P =  .02) (Figure 2). There was no dif-
ference in levels of IFN-γ, λ1, λ2, and λ3 or other cytokines at 
baseline or on treatment.
Responders and nonresponders exhibited similar frequencies 
of CD4 and CD8 effector T-cell subsets throughout the 3 time-
points (Figure  5). In contrast, T-reg cell frequencies differed 
between the 2 groups: although there was no difference at base-
line, T-reg frequency decreased in responders and increased in 
nonresponders during treatment (P = .02 for difference in fold 
change) (Figure 5).
DISCUSSION
There are few studies that have described the characteristics of 
individuals who fail to respond to DAAs, and the majority of 
these have focused on HCV viral resistance [17, 18]. We show 
that in patients with decompensated cirrhosis, nonrespond-
ers to DAA therapy did not have baseline HCV resistance 
mutations nor poorer adherence than responders. However, the 
data reported here indicate that there is an association between 
the response to DAA and a number of immunological param-
eters. CXCL-10 serum levels and NK immunophenotype were 
particularly informative.
 CXCL-10 is a chemokine known to be released from HCV-
infected livers as a result of increased ISG expression. Serum 
CXCL-10 is highly correlated with intrahepatic CXCL-
10 mRNA expression [14] and is often used as a surrogate 
marker of hepatic ISG expression [19]. Thus, increased serum 
CXCL-10 and elevated pretreatment ISG expression are both 
predictors of nonresponse to pegylated IFN-based treatment 
[20, 21].
We found that in patients with decompensated cirrhosis, 
elevated baseline CXCL-10 was associated with nonresponse 
to DAAs. There are few data on CXCL-10 levels in the context 
of decompensation because these patients are often excluded 
from studies [22]. In our study, the majority of patients with 
decompensation responded to DAAs, and this group had 
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significantly lower CXCL-10 levels than a noncirrhotic com-
parison group. The lower CXCL-10 levels in decompensation 
may reflect the reduced number of hepatocytes; lower HCV 
RNA and transaminase levels are also seen in decompensated 
disease [23]. However, the nonresponder patients had similar 
CXCL-10 levels to the noncirrhotic group, in whom SVR rates 
exceed 95%.
Directly acting antiviral treatment resulted in a decrease in 
CXCL-10 in all nonresponders but an increase in CXCL-10 lev-
els in responders, with the fastest virological responders show-
ing the greatest increase. Our findings that elevated CXCL-10 
at baseline is associated with nonresponse, but upregulation of 
CXCL-10 on treatment is associated with response is directly 
analogous to the well reported mechanism of ISG expression as 
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a predictor of response to pegylated IFN [14]. That IFN signal-
ing still plays a role even in IFN-free treatment fits with hepatic 
gene expression data from Meissner et al [24], who showed that 
hepatic IFN-α expression increased during successful IFN-
free treatment for HCV. At the end of 12 weeks of treatment, 
a cross-sectional comparison between responders and non-
responders showed that hepatic ISG expression was higher in 
responders [24]. These authors suggest an ongoing role for IFN 
signaling even during DAA therapy for HCV.
Our finding that CXCL-10 increased in responders on DAA 
treatment differs from the results of Meissner et  al [25] and 
Spaan et  al [25] who found a consistent decline in CXCL-10 
in all patients as HCV RNA declined. A  potential explana-
tion for our dissimilar findings is that all of our patients had 
decompensated cirrhosis, whereas in the other studies most 
patients were noncirrhotic, and none were decompensated. 
Two pathways of hepatic CXCL-10 induction are known: (1) 
a direct signaling pathway where recognition of HCV RNA by 
pattern recognition receptors triggers transcription within the 
hepatocyte; and (2) indirect production in response to type I, 
II, and III IFNs produced by Kupffer cells, stellate cells, and 
sinusoidal epithelial cells (nonparenchymal cells [NPCs]) [26]. 
In decompensated cirrhosis, with a reduced hepatocyte mass 
and elevated IFN-γ levels [27], CXCL-10 production may be 
primarily driven by the production of IFNs by NPC. We also 
saw a significant elevation in CXCL-10 level at the end of treat-
ment in nonresponders. This may represent an ongoing innate 
immune response to low-level residual HCV viremia before 
overt virological relapse.
The parallel with the relationship linking overactivation 
of the innate immune system with nonresponse to pegylated 
IFN extends to our findings in NK cells. We found that non-
responders demonstrated a different NK cell profile compared 
with responders, with proportions of NK cells expressing the 
natural cytotoxicity receptor NKp30 higher in nonrespond-
ers at all timepoints. NKp30 is an activation receptor that is 
upregulated in response to IFN-α [28, 29], and high NKp30 
expression before IFN-based therapy predicts nonresponse to 
treatment and is analogous to upregulated ISG expression as 
a marker of overactivation of the innate immune system [30]. 
We also saw a decline in T-reg cells over the course of treatment 
in responders but an increase in nonresponders. T-regulatory 
cells are suppressed by IFN, and their activity favors HCV 
chronicity, so upregulation of IFN signaling during treatment 
in responders could explain the decline in T-reg cells seen in 
this group [31].
That responders had a higher frequency of the CD56−CD16+ 
NK cells subset was an unexpected finding. The CD56−CD16+ 
subset of NK cells is enriched in patients with HIV and HCV 
infection and is a dysfunctional subset with impaired cytotox-
icity and cytokine production and a loss of polyfunctionality 
likened to exhaustion seen in T cells [32]. This subset declined 
over the course of treatment in responders while increasing in 
nonresponders.
We considered other causes for the difference in response 
between the groups. We first considered the number of patients 
with G3 infection. G3, which has been most challenging in the 
DAA era, was slightly overrepresented in the nonresponder 
group, although this was not statistically significant. Most of the 
patients with G3 were treated with sofosbuvir/ledipasvir and 
ribavirin, which is not a currently recommended treatment, but 
it was the only option available at the time of the study. It seems 
unlikely that this was the main reason for nonresponse because 
the majority of G3 patients in the responder group also received 
this combination. We also considered whether the higher pro-
portion of patients with G3 in the nonresponders could explain 
the immunological differences observed. Although CXCL-
10 levels are lower in genotype 3 HCV than G1 [20], G3 does 
upregulate IFN signaling in NPCs to a greater extent than G1 
HCV [33]. Because we hypothesize that in decompensated 
cirrhosis the source of CXCL-10 is NPCs, this could partially 
explain the higher levels seen in the nonresponders.
Another factor to consider is the relatively higher number 
of hepatocellular carcinoma (HCC) cases in the nonresponder 
group. This difference was also not significant, although with 
small group numbers type 2 errors may occur. The presence of 
HCC may play a role, because HCC has recently been revealed 
as a risk factor for failing DAA therapy [34]. This could either 
be because HCC serves as a sanctuary for virus, or it could be 
because the immune deficits that predispose to HCC also pre-
dispose to nonresponse to DAAs. An immune evasion tech-
nique of HCC is to increase myeloid-derived suppressor cells 
that inhibit NK via NKp30; elevated NK NKp30 expression in 
HCC is also associated with worse prognosis [35, 36].
Limitations of our study include the small number of sub-
jects, although because our patients had decompensated cir-
rhosis, we report a relatively high number of nonresponders. 
The differences that we describe between responders and non-
responders may not be generalizable to the general population 
of noncirrhotic patients with HCV. We were also confined to 
investigating the peripheral immune response rather than the 
hepatic response.
CONCLUSIONS
With well tolerated DAAs, response rates in patients with 
decompensated cirrhosis remain lower than in those without 
cirrhosis. This study shows that responders and nonrespond-
ers to DAAs differ in their immunological characteristics and 
not all nonresponse is a function of poor adherence. Although 
nonresponders may subsequently achieve an SVR with longer 
course of treatment [37], failing 12 weeks of treatment is 
undesirable because there is a risk of further decompensa-
tion and death. Baseline CXCL-10 is a simple test that could 
predict response to therapy in the majority of patients with 
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decompensated cirrhosis and allow an extended duration of 
treatment in patients with higher levels.
In summary, we show that in patients with decompensated 
cirrhosis, nonresponders to DAA therapy displayed differences 
in CXCL-10 profile and NK phenotype. This supports an ongo-
ing role for the innate immune system even in IFN-free treat-
ment for HCV.
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